Tesamorelin Therapy

Tesamorelin binds to GHRH receptors on the anterior pituitary gland, stimulating the synthesis and secretion of endogenous growth hormone. The trans-3-hexenoic acid modification at the N-terminus provides enhanced resistance to enzymatic degradation by dipeptidyl peptidase, extending its biological activity. The resulting increase in growth hormone triggers hepatic IGF-1 production, which mediates effects on body composition. Tesamorelin has demonstrated a particular ability to reduce visceral adipose tissue (the metabolically harmful fat surrounding abdominal organs) while preserving subcutaneous fat to a greater degree. It may also improve lipid profiles and reduce liver fat content, contributing to broader metabolic health improvements.

Tesamorelin is commonly sought by patients with significant visceral fat accumulation, particularly those for whom this represents a metabolic health concern rather than purely a cosmetic issue. Its FDA approval gives patients and providers confidence in its safety and efficacy data. Individuals who prefer peptides with regulatory approval and robust clinical trial data gravitate toward tesamorelin over less-studied alternatives.

Tesamorelin is administered via subcutaneous injection in the abdominal area, typically once daily. The FDA-approved protocol involves daily injection of 2 mg. Treatment courses in clinical trials lasted 26 weeks, with some extending longer. Response is typically assessed after 12 to 16 weeks, and therapy may be discontinued if meaningful abdominal fat reduction has not been achieved by that point.